Enanta Pharmaceuticals to Unveil Positive Phase 2 Data for RSV Drug…

Event summary

Enanta Pharmaceuticals will present Phase 2 trial data for zelicapavir, an oral, once-daily N-protein inhibitor for RSV, at IDWeek 2026 on October 22, 2026.
The poster presentation will highlight zelicapavir's efficacy in decreasing time to RSV symptom resolution, hospitalization, and viral load in high-risk adults.
Zelicapavir is part of Enanta's pipeline focused on developing first-in-disease and best-in-disease treatments for RSV.

The big picture

Enanta Pharmaceuticals is positioning itself as a key player in the RSV treatment space with zelicapavir, following its success in hepatitis C with glecaprevir. The Phase 2 data presentation at IDWeek 2026 is a critical milestone in assessing the drug's potential to address a significant unmet need in respiratory infections. The company's focus on novel small molecule drugs for viral infections aligns with broader industry trends toward targeted therapies for infectious diseases.

What we're watching

Clinical Progress: The pace at which zelicapavir advances through Phase 3 trials and potential regulatory filings will determine its commercial viability.
Market Positioning: Whether Enanta can establish zelicapavir as a leading RSV treatment in a competitive landscape with other emerging therapies.
Financial Impact: How the success of zelicapavir could influence Enanta's revenue streams, particularly in light of its existing royalties from HCV products.